Shanghai MicroPort EP MedTech's (SHA:688351) forecasts its attributable profit will rise 76% to 106% to between 30 million yuan and 35 million yuan in the first half from 17 million yuan in the prior-year period, according to a Wednesday filing with the Shanghai bourse.
Operating income at the medical device company is seen to grow 8.4% to 16% to between 215 million yuan and 230 million yuan during the half, from 198.4 million yuan in the year-ago period.
The upbeat forecast is attributable to steady growth in its overall sales volume following the launch of its TrueForce pressure monitoring radiofrequency ablation catheters, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。